Brahma-related gene 1 (BRG1) is one of two mutually exclusive ATPases that function as the catalytic subunit of human SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeling enzymes. BRG1 has been identified as a tumor suppressor in some cancer types but has been shown to be expressed at elevated levels, relative to normal tissue, in other cancers. Using TCGA (The Cancer Genome Atlas) prostate cancer database, we 
is lacking, and there is considerable controversy about screening methods (Dong & Ji, 2017; Kinsella et al., 2018; Lee & Shen, 2015; Packer & Maitland, 2016; Tabayoyong & Abouassaly, 2015; Wang, Toivanen, Bergren, Chambon, & Shen, 2014) . Continued efforts to identify molecular markers that distinguish between tumors that will remain latent, progress slowly, or progress aggressively are needed (Arriaga-Canon et al., 2018; Filella, Fernandez-Galan, Fernandez Bonifacio, & Foj, 2018) .
There are two closely related, mutually exclusive ATPases that function as the catalytic subunits of the human/mammalian SWItch/ Sucrose NonFermentable (SWI/SNF) chromatin remodeling enzymes, termed Brahma-related gene 1 (BRG1) and Brahma (BRM; Imbalzano, Khavari, Peterson, Tamkun, Mendel, & Crabtree, 1993; Kwon, Imbalzano, Khavari, Kingston, & Green, 1994; Muchardt & Yaniv, 1993; W. Wang et al., 1996) . These enzymes are widely utilized in the cell to regulate gene expression, replication, repair, recombination, and higher-order genome organization. Not surprisingly, both enzymes have been implicated in diverse types of cancer (Hodges, Kirkland, & Crabtree, 2016; Savas & Skardasi, 2018; Wu et al., 2017) . There is considerable evidence that both the BRG1 and the BRM enzymes are mutated or exhibit altered expression in many cancers, but to date, the evidence suggests that the consequences of these changes vary widely depending on the type of cancer.
Loss of BRG1 function has been shown in a number of cancers, most notably small cell carcinoma of the ovary, hypercalcemic type (Jelinic et al., 2014; Kupryjanczyk et al., 2013; Ramos et al., 2014; Witkowski et al., 2014) , and non-small-cell lung cancers (Fukuoka et al., 2004; Medina et al., 2004; Reisman, Sciarrotta, Wang, Funkhouser, & Weissman, 2003) , and results in loss of a number of cell functions related to tumor suppression. BRM loss has been implicated in a number of tumor types, and the idea of targeting BRM in BRG1-deficient cancers has received attention as a potential therapeutic strategy (Hohmann & Vakoc, 2014; Oike et al., 2013; Wilson et al., 2014) . In contrast, there is emerging evidence that BRG1 is expressed at elevated levels in some tumors relative to normal tissue. This includes disparate tumor types such as breast cancer, melanoma, neuroblastoma, colorectal cancer, and prostate cancer (Bai et al., 2013; Do et al., 2016; Jubierre et al., 2016; Lin, Wong, Martinka, & Li, 2010; Saladi et al., 2010; Watanabe, Semba, & Yokozaki, 2011; Wu et al., 2015) . Though increased expression of mutated proteins could be consistent with a tumor suppressive function, there is no evidence of prevalent BRG1 or BRM mutation in breast cancer or melanoma (Cancer Genome Atlas, 2012; Cancer Genome Atlas, 2015) , where such analysis has been reported. Elevated BRG1 expression has been linked to numerous pathways converging on cell proliferation and survival, including sonic hedgehog (SHH) and WNT signaling, the PI3K/AKT pathway, and regulation of lipogenesis and ATP-binding cassette (ABC) transporter induction (reviewed in [Wu et al., 2017] ).
These results indicate that, if properly delivered, inhibitors of BRG1 function may represent a potential therapeutic approach to certain cancers. PFI-3, a small molecule bromodomain inhibitor with structural specificity for three bromodomain containing subunits of the mammalian SWI/SNF enzymes (BRG1, BRM, and polybromo-1, also called BAF180; Vangamudi et al., 2015) has been shown to modulate certain cell differentiation transitions, (Fedorov et al., 2015; Gerstenberger et al., 2016) but has no effect whatsoever on cancer cell proliferation (Vangamudi et al., 2015; . However, promising results for inhibition of cancer cell proliferation have resulted from studies of an as yet structurally undefined inhibitor of the SNF2 family of ATPases called ADAADi (active DNA-dependent ATPase A Domain inhibitor). ADAADi is a chromatographically separable byproduct of the bacterial aminoglycoside-phosphotransferase (APH) action upon aminoglycosides (Dutta et al., 2012; Muthuswami et al., 2000) . ADAADi has largely been used as a biochemical probe to help define enzymatic activities of SNF2 ATPases in vitro (Dutta et al., 2012; Muthuswami et al., 2000; Sharma, Bansal, Haokip, Goel, & Muthuswami, 2015) , and it therefore functions as an inhibitor of other adenosine triphosphate (ATP)-dependent activities of these enzymes, such as chromatin remodeling (Muthuswami et al., 2000) . In tissue culture, ADAADi inhibits cancer cell proliferation and survival (Dutta et al., 2012; Wu, Madany et al., 2016 ) and there appears to be some specificity of ADAADi for BRG1, as both ADAADi and shRNA-mediated knockdown of BRG1 inhibited proliferation, but there was no additive effect of the inhibitor plus BRG1 knockdown (Wu, Madany et al., 2016) . This result suggests that even if other related ATPases are contributing to cell proliferation and survival, their contributions are relatively minor. In addition to effects on cancer cell proliferation, ADAADi phenocopies BRG1 knockdown in demonstrating essential functional roles for BRG1 in cancer cell metabolism and in druginduced activation of ABC transporter proteins linked to chemoresistance (Wu, Madany et al., 2016; .
A specific BRG1-targeting molecule may therefore be of therapeutic value in the treatment of certain cancers.
In this report, we interrogated the The Cancer Genome Atlas Goldman et al., 2018) . Correlations between BRG1 and BRM messenger RNA (mRNA) levels in patient tumors were plotted using GEPIA (Gene Expression Profiling Interactive Analysis), a web-based tool for analysis of TCGA datasets (gepia.cancer-pku.cn; Tang et al., 2017) . GEPIA was also used to draw boxplots and to correlate diseasefree survival (also called relapse-free survival) with gene expression.
GEPIA uses the Log-rank test, or the Mantel-Cox test for survival hypothesis testing. The Cox proportional hazard ratio and the 95% confidence interval information are also calculated. BRG1 and BRM mutations in TCGA prostate tumors were analyzed by CBioPortal (http://www.cbioportal.org; Cerami et al., 2012; Gao et al., 2013) .
Correlations between Gleason Scores and gene expression were done using Betastasis (www.betastasis.com/prostate_cancer/tcga_prad_from_ gdc). Conclusions about human subjects are derived from data in public databases where patient information is deidentified.
| Synthesis and purification of ADAADi
ADAADi for cell culture studies was synthesized and purified as described (Dutta et al., 2012) . ADAADi for animal studies was synthesized and purified as described (Muthuswami et al., 2000) .
| Cell lines
Human PRAD cell line PC3 was purchased from ATCC or from NCCS, Pune, India and maintained in Dulbecco's modified Eagle's Medium supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin Amphotericin cocktail at 37°C in the presence of 5% CO 2 . KLK3), which showed a significant elevation in expression in tumors, and SUN1, an inner nuclear envelope protein not previously linked to prostate cancer, which showed no significant difference (Table 1) .
| Cell viability assay
Boxplots showing the ranges for BRG1 and BRM mRNA expression in all TCGA samples (n = 492 for tumors, n = 52 for normal) reinforced the conclusion that BRG1 mRNA expression is elevated in tumor samples compared with normal tissue while the converse is true for BRM mRNA (Figure 1a ). The UCSC Xena tool was used to determine whether any correlation between BRG1 and BRM mRNA expression in prostate cancer exists; the results clearly show no correlation across the data set ( Figure 1b ). To evaluate protein expression, we queried published proteomic data for BRG1 from 28 prostate tumor and eight normal prostate tissue samples (Iglesias-Gato et al., 2016) .
We were unable to identify similar proteomic data for BRM. The data show a statistically significant increase in BRG1 protein expression in the tumor relative to normal tissue ( Table 2 ) that matches the magnitude of the increase in BRG1 mRNA determined from analyzing the TCGA data set (Table 1 ; Figure 1a ).
We examined sequence data for the BRG1 and BRM coding sequences to determine whether any of the patient tumors were Traditionally, prostate tumors have been graded on the
Gleason scale (Gleason, 1966; Gleason & Mellinger, 1974; Mellinger, Gleason, & Bailar, 1967) . In this microscopic evalua- F I G U R E 1 BRG1 mRNA expression in prostate cancer patient tissue is elevated compared with that in normal prostate tissue while BRM mRNA expression in prostate cancer patient tissue is reduced compared with that in normal prostate tissue. All data were extracted from the prostate adenocarcinoma TCGA data set. Plots were generated with GEPIA software (Tang et al., 2017) . Li et al., 2006) . Although the TCGA data set did not contain information on BRM protein levels, a prior report revealed that BRM protein levels did not correlate with increased BRG1 protein in patient samples (Sun et al., 2007) . A recent survey of multiple tumor types indicated that BRG1 expression was elevated in tumors whereas BRM was not (Guerrero-Martinez & Reyes, 2018) . Mechanistically, it appears that there is a direct correlation between BRG1 mRNA and F I G U R E 2 Schematic diagram of the location of BRG1 and BRM somatic mutations present in TCGA prostate tumor patients relative to known domains of BRG1 and BRM proteins. CBioPortal (Cerami et al., 2012; Gao et al., 2013) Normalized Disease-free Survival F I G U R E 3 BRG1 mRNA levels (a) but not BRM mRNA levels (b) inversely correlate with prostate tumor patient survival. Kaplan-Meier plots shown are based on an analysis of TCGA prostate patient data using GEPIA (Tang et al., 2017) . The blue line labeled "Low" is the patients with the lowest quartile of mRNA levels; the red line labeled "High" is the patients with the highest quartile of mRNA levels. A Log-rank test, the Mantel-Cox test, was used to determine p values. HR, hazard ratio. BRM: Brahma; GEPIA: Gene Neither BRG1 nor BRM is frequently mutated in the patient tumors.
This result is consistent with and extends a prior report finding no mutations in BRG1 coding sequences from 21 patient tumors (Valdman et al., 2003) . Of the mutations identified in the TCGA database, a G775D alteration in BRG1 indicates a mutation in motif I of the conserved Snf2 ATPase domain (Flaus, Martin, Barton, & Owen-Hughes, 2006 ). This residue is not conserved amongst the Snf2 family proteins. Nevertheless, we would predict that this mutation would render the protein inactive based on our prior structure-function studies (Nongkhlaw, Gupta, Komath, & Muthuswami, 2012) . The I1214L mutation identified in BRG1 is outside motif Prior work has demonstrated that high BRG1 mRNA expression inversely correlates with patient survival in breast cancer (Bai et al., 2013; Do et al., 2016; , colorectal cancer (S. Lin et al., 2016; Pyo, Son, Oh, & Kim, 2018) , and neuroblastoma (Jubierre et al., 2016) . In addition, BRG1 is required for various aspects of cancer cell survival, proliferation, and function in HeLa cells (Naidu, Love, Imbalzano, Grossman, & Androphy, 2009 ), leukemia cells (Buscarlet et al., 2014; J. Shi et al., 2013) neuroblastoma (Jubierre et al., 2016) , melanoma (Keenen, Qi, Saladi, Yeung, & de la Serna, 2010; H. Lin et al., 2010; Vachtenheim, Ondrusova, & Borovansky, 2010) , and certain medulloblastoma tumors (Shi, Wang, Gu, Xuan, & Wu, 2016) . Recent evidence indicates that the fusion between the TMPRSS2 gene and the ETS family transcription factor, ERG, that occurs in half of the prostate cancers, mediates its oncogenic effect at least in part by interacting with the human SWI/SNF enzymes and redirecting its chromatin interactions across the genome (Sandoval et al., 2018) . Thus the chromatin remodeling enzyme and presumably its enzymatic function is a required component contributing to prostate oncogenesis. Collectively, the data contrast with the idea of BRG1 acting as a tumor suppressor in all cancer types, support the idea of context-dependent function of SWI/SNF ATPases in cancer, and support the idea that BRG1 and/or BRM can, in some contexts, be drivers of oncogenesis (Wu et al., 2017) .
We compared BRG1 expression to Gleason score, the commonly used staging system for prostate tumors (Mellinger et al., 1967) In this report, we demonstrate that an inhibitor that shows specificity for BRG1 can be an effective tool in inhibiting prostate cancer cell survival in tissue culture and in xenografted prostate tumors. Prior studies have demonstrated that ADAADi is effective against numerous cancer cell types in culture (Dutta et al., 2012; , but here we show that it is effective in an animal tumor model. As this study was being completed, Ding et al. (2018) published a report identifying a synthetically lethal relationship in prostate cancer between BRG1 and the PTEN tumor suppressor (J. Li et al., 1997; Steck et al., 1997) . They determined that phosphatase and tensin homolog (PTEN) loss sensitized the prostate cancer cells to BRG1 depletion in culture and in mouse tumor models with PTEN deficiency. Of particular note, PFI-3, a bromodomain-targeting drug specific for BRG1, BRM, and another SWI/ SNF subunit called Polybromo (Gerstenberger et al., 2016 ) that has no effect on the proliferation of various cancer cell types (Vangamudi et al., 2015; , inhibited PTEN-deficient prostate cancer cells in culture and compromised tumor growth in vivo when introduced by oral gavage to mice containing xenografts seeded by PTEN-deficient prostate cancer cells. Our work and the work of Ding et al. (2018) therefore extend the proof-of-principle that targeting BRG1 can be an effective strategy for cancer treatment. (Ding et al., 2018) . In addition, in triple negative breast cancer, BRG1 is specifically required for the upregulation of lipid and fatty acid synthesis enzymes that are required to produce elevated levels of these building blocks for rapid cell division; knockdown or inhibition of BRG1 reduced overall de novo lipid synthesis in the cancer cells but not in breast epithelial cells (Wu, Madany et al., 2016) . Another example of a cancerspecific role for BRG1 comes for other studies in triple negative breast cancer cells where it was shown that BRG1 mediates the raising the possibility that a BRG1 inhibitor could be an effective adjuvant treatment to classical chemotherapy drugs . The data support the idea that inhibition or reduction of BRG1 could preferentially impair cancer cell growth and function relative to normal cells. Delivery, like with many inhibitory drugs, will be an issue that will require further development. However, it is apparent based on the work presented here and elsewhere that direct delivery of the inhibitor to the tumor can be effective in tumor reduction without impairing lifespan or apparent health of the treated individual. Presumably, this means that any effects of the treatment on the functions of BRG1 in normal cells exposed to the inhibitor were minimal or nonexistent.
Finally, this study will be greatly advanced once the inhibitory molecule(s) present in the ADAADi preparation are identified. Work in our labs continues to address this problem. In addition to better defining ADAADi, our work indicates that screens of chemical libraries should be performed to identify novel inhibitors of BRG1, which we would predict would have immediate preclinical relevance for future therapeutic approaches to cancers where BRG1 expression is elevated relative to normal tissue.
